Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CalxPlus is a dietary mineral supplement developed and marketed by Ceres Pharma, primarily in the Belgian and European markets. It is formulated as a combination of calcium carbonate, vitamin D3 (cholecalciferol), and vitamin K1 (phytomenadione). The supplement is intended to support bone health and prevent osteoporosis by providing essential components for bone mineralization. Calcium carbonate provides elemental calcium (600 mg), while vitamin D3 (10 μg) enhances intestinal calcium absorption. Vitamin K1 (65 μg) is included to facilitate the binding of calcium to the bone matrix via the carboxylation of osteocalcin. CalxPlus is available in various oral formulations, including chocolate-flavored chewable tablets and capsules, specifically targeting individuals with calcium deficiency or those requiring bone density support.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on CalxPlus.